„In-situ-Split“- (ISS) Leberresektion: Neue Aspekte zu Technik und
                    Indikation

S. A. Lang; M. Loss; H. J. Schlitt

doi:10.1055/s-0032-1328742

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, Table of Contents

Zentralbl Chir 2014; 139(2): 212-219
DOI: 10.1055/s-0032-1328742

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

„In-situ-Split“- (ISS) Leberresektion: Neue Aspekte zu Technik und Indikation

“In-situ Split” (ISS) Liver Resection: New Aspects of Technique and Indication

S. A. Lang

Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg, Deutschland

,

M. Loss

Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg, Deutschland

,

H. J. Schlitt

Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Die Kombination von rechtsseitiger Pfortaderligatur mit kompletter Parenchymdissektion („In-situ-Split“, ISS) zur Hypertrophieinduktion des links-lateralen Leberlappens ist eine neue Strategie, um primär funktionell irresektable Lebertumoren in einen resektablen Zustand zu überführen. Bislang vorhandene Daten zeigen eine Vergrößerung der Restleber innerhalb eines Zeitraums von 7(− 9) Tagen um bis zu 60–80 %. Ein derart invasives Konzept mit 2 operativen Eingriffen innerhalb kurzer Zeit wirft naturgemäß viele Fragen auf. Unter Einbeziehung der wenigen bislang vorhandenen Literatur zum ISS sowie eigener Erfahrungen mit dieser Prozedur werden technische Diskussionspunkte wie u. a. die Adhäsionsprophylaxe durch Fremdmaterial an der Resektionsfläche, die Möglichkeit der laparoskopischen Primäroperation sowie die Wahl des optimalen Zeitpunkts für die Komplettierungsoperation erörtert. Ferner diskutieren wir Aspekte bezüglich Umfang und Intensität der präoperativ notwendigen Diagnostik. Abschließend werden offene Fragen hinsichtlich der Indikationsstellung wie beispielsweise der Einfluss vorangegangener Chemotherapie oder die Anwendung des ISS bei Patienten mit Leberzirrhose angerissen. Die Darstellung von Chancen und Risiken des neuen Konzepts im Kontext von Indikation und technischer Durchführung soll dazu beitragen, einer größeren Zahl von Patienten mit marginal oder primär irresektablen Lebertumoren die potenziell kurative Option des „In-situ-Splits“ zu ermöglichen.

Abstract

The combination of right portal vein ligation with complete parenchyma dissection (“in-situ split”, ISS) for rapid hypertrophy induction of the left-lateral liver lobe is a novel strategy to convert primarily irresectable liver tumours into a resectable stage. Available data so far show a 60–80 % growth induction of the remnant liver within 7(− 9) days. Certainly, a novel concept that comprises two operations within a very short time period raises questions. Based on the very few literature reports that have been published so far, as well as our own experience, we here discuss technical issues such as the use of a plastic sheet on the resection margin, the possibility of laparoscopic dissection and the timing of the second operation. Moreover, aspects of the preoperative diagnostic work-up that is necessary are assessed. Finally, open questions, e.g., concerning the influence of preoperative chemotherapy and the use of ISS in patients with cirrhosis are evaluated. In summary, the assessment of chances and risks of this novel concept with regard to indication and technical issues helps to provide the potentially curative option of the “in-situ split” procedure to more patients with marginal or even irresectable liver tumours.

Schlüsselwörter

zweizeitige Leberresektion - Resektabilität - In-situ-Split - Hypertrophie - Technik - Indikation

Key words

liver resection in two steps - resectability - in-situ splitting - hypertrophy - technique - indication

Full Text

References

Literatur
1 Choi SB, Kim KS, Choi JY et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16: 3048-3056
2 de Haas RJ, Wicherts DA, Andreani P et al. Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg 2011; 253: 1069-1079
3 Seehofer D, Neuhaus P. [Current status of multimodal therapy for colorectal liver metastases]. Zentralbl Chir 2011; 136: 343-351
4 Guglielmi A, Ruzzenente A, Conci S et al. How much remnant is enough in liver resection?. Dig Surg 2012; 29: 6-17
5 Knoefel WT, Alexander A, Tustas RY et al. [Stem cell-induced liver regeneration]. Zentralbl Chir 2013; 138: 166-172
6 Tanaka K, Shimada H, Matsuo K et al. Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 2007; 33: 329-335
7 Lam VW, Spiro C, Laurence JM et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012; 19: 1292-1301
8 Palavecino M, Chun YS, Madoff DC et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145: 399-405
9 Tanaka K, Shimada H, Matsuo K et al. Regeneration after two-stage hepatectomy vs. repeat resection for colorectal metastasis recurrence. J Gastrointest Surg 2007; 11: 1154-1161
10 Tsai S, Marques HP, de Jong MC et al. Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 2010; 12: 262-269
11 van Lienden KP, van den Esschert JW, de Graaf W et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013; 36: 25-34
12 Wicherts DA, de Haas RJ, Andreani P et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010; 97: 240-250
13 Schnitzbauer AA, Lang SA, Goessmann H et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255: 405-414
14 de Santibañes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg 2012; 255: 415-417
15 Alvarez FA, Ardiles V, Sanchez Claria R et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): tips and tricks. J Gastrointest Surg 2013; 17: 814-821
16 Cavaness KM, Doyle MB, Lin Y et al. Using ALPPS to induce rapid liver hypertrophy in a patient with hepatic fibrosis and portal vein thrombosis. J Gastrointest Surg 2013; 17: 207-212
17 Hahn O, Dudas I, Pajor P et al. [ALPPS (Associated Liver Partition and Portal vein ligation for Staged hepatectomy) – faster and more significant liver hypertrophy]. Magy Seb 2013; 66: 21-26
18 Knoefel WT, Gabor I, Rehders A et al. In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. Br J Surg 2013; 100: 388-394
19 Li J, Girotti P, Königsrainer I et al. ALPPS in right trisectionectomy: a safe procedure to avoid postoperative liver failure?. J Gastrointest Surg 2013; 17: 956-961
20 Machado MA, Makdissi FF, Surjan RC. ALPPS procedure with the use of pneumoperitoneum. Ann Surg Oncol 2013; 20: 1491-1493
21 Oldhafer KJ, Donati M, Maghsoudi T et al. Integration of 3D volumetry, portal vein transection and in situ split procedure: a new surgical strategy for inoperable liver metastasis. J Gastrointest Surg 2012; 16: 415-416
22 Sala S, Ardiles V, Ulla M et al. Our initial experience with ALPPS technique: encouraging results. Updates Surg 2012; 64: 167-172
23 Konopke R, Kersting S, Bergert H et al. Contrast-enhanced ultrasonography to detect liver metastases: a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis 2007; 22: 201-207
24 Loss M, Schneider J, Uller W et al. Intraoperative high resolution linear contrast enhanced ultrasound (IOUS) for detection of microvascularization of malignant liver lesions before surgery or radiofrequeny ablation. Clin Hemorheol Microcirc 2012; 50: 65-77
25 Nadalin S, Testa G, Malago M et al. Volumetric and functional recovery of the liver after right hepatectomy for living donation. Liver Transpl 2004; 10: 1024-1029
26 Ono Y, Kawachi S, Hayashida T et al. The influence of donor age on liver regeneration and hepatic progenitor cell populations. Surgery 2011; 150: 154-161
27 Kanzler S, Teufel A, Galle PR. [Liver function test to predict hepatic failure after liver resection–expensive and without clinical relevance?]. Zentralbl Chir 2007; 132: 267-273
28 Truant S, Oberlin O, Sergent G et al. Remnant liver volume to body weight ratio > or = 0.5 %: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg 2007; 204: 22-33
29 Tongyoo A, Pomfret EA, Pomposelli JJ. Accurate estimation of living donor right hemi-liver volume from portal vein diameter measurement and standard liver volume calculation. Am J Transplant 2012; 12: 1229-1239
30 Muhi A, Ichikawa T, Motosugi U et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011; 34: 326-335
31 Ramos E, Valls C, Martinez L et al. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?. Ann Surg Oncol 2011; 18: 2654-2661
32 Cucchetti A, Ercolani G, Vivarelli M et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006; 12: 966-971
33 Farges O, Malassagne B, Flejou JF et al. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg 1999; 229: 210-215
34 Kawano Y, Sasaki A, Kai S et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008; 15: 1670-1676
35 Kishi Y, Zorzi D, Contreras CM et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17: 2870-2876
36 Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990
37 Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072
38 Bachellier P, Rosso E, Pessaux P et al. Risk factors for liver failure and mortality after hepatectomy associated with portal vein resection. Ann Surg 2011; 253: 173-179
39 Lang H, Sotiropoulos GC, Brokalaki EI et al. Left hepatic trisectionectomy for hepatobiliary malignancies. J Am Coll Surg 2006; 203: 311-321
40 van Gulik TM, Ruys AT, Busch OR et al. Extent of liver resection for hilar cholangiocarcinoma (Klatskin tumor): how much is enough?. Dig Surg 2011; 28: 141-147